COMPASS Pathways plc — fact timeline

COMPASS Pathways plc shareholders approved Advisory approval of named executive officer compensation at the 2026-05-27 meeting.

“Proposal 10. To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers for the year ended December 31, 2025. FOR AGAINST WITHHELD BROKER NON-VOTES 58,291,006 455,870 133,182 76,043,237 At the AGM, the Company’s shareholders approved, on a non-binding and advisory basis, the compensation of the Company’s named executive officers for the year ended December 31, 2025.”

COMPASS Pathways plc shareholders approved Advisory approval of U.K. statutory directors' remuneration report at the 2026-05-27 meeting.

“Proposal 9. To receive and approve, on a non-binding, advisory basis, the Company's U.K. statutory directors’ remuneration report for the year ended December 31, 2025. FOR AGAINST WITHHELD BROKER NON-VOTES 58,379,024 383,453 117,581 76,043,237 At the AGM, the Company’s shareholders approved on an advisory basis, the directors’ remuneration report for the year ended December 31, 2025.”

COMPASS Pathways plc shareholders approved Receive U.K. statutory annual accounts and note no dividend at the 2026-05-27 meeting.

“Proposal 8. To receive the U.K. statutory annual accounts and report for the fiscal year ended December 31, 2025 and to note that the directors do not recommend the payment of any dividend for the year ended December 31, 2025. FOR AGAINST WITHHELD BROKER NON-VOTES 58,705,133 70,478 104,447 76,043,237 At the AGM, the shareholders approved the receipt of the U.K. statutory annual accounts and reports for the year ended December 31, 2025 and to note that the directors do not recommend the payment of any dividend for the year ended December 31, 2025.”

COMPASS Pathways plc shareholders approved Authorize Audit and Risk Committee to determine auditors' remuneration at the 2026-05-27 meeting.

“Proposal 7. To authorize the Audit and Risk Committee to determine the auditors’ remuneration for the year ending December 31, 2026. FOR AGAINST WITHHELD BROKER NON-VOTES 58,743,672 62,739 73,647 76,043,237 At the AGM, the shareholders authorized the Audit and Risk Committee to determine the auditors’ remuneration for the year ending December 31, 2026.”

COMPASS Pathways plc shareholders approved Ratification of PwC US as independent registered public accounting firm at the 2026-05-27 meeting.

“Proposal 6. Ratification, on a non-binding, advisory basis, of the appointment of PricewaterhouseCoopers LLP, a Delaware limited liability partnership (“PwC US”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. FOR AGAINST WITHHELD BROKER NON-VOTES 58,758,214 55,042 66,802 76,043,237 At the AGM, the shareholders ratified the appointment of PwC US as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

COMPASS Pathways plc shareholders approved Re-appointment of PwC UK as U.K. statutory auditors at the 2026-05-27 meeting.

“Proposal 5. To re-appoint PricewaterhouseCoopers LLP, an English limited liability partnership (“PwC UK”), as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders. FOR AGAINST WITHHELD BROKER NON-VOTES 58,755,739 56,042 68,277 76,043,237 At the AGM, the shareholders approved the re-appointment of PwC UK as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders.”

COMPASS Pathways plc shareholders approved Election of Directors at the 2026-05-27 meeting.

“Proposal 1. To re-elect Justin Gover as a Director of the Company. FOR AGAINST WITHHELD BROKER NON-VOTES 58,630,954 146,737 102,367 76,043,237 At the AGM, Justin Gover was duly re-elected.”

COMPASS Pathways plc reported for the three months ended March 31, 2026 results: net income $91.2 million, or $0.71 net income per share (basic) and $0.30 net loss per share (diluted), EPS $0.71 net income per share (basic) and $0.30 net loss per share (diluted). Guidance reaffirmed.

“Compass Pathways plc (the “Company”) issued a press release announcing the Company's financial results for the three months ended March 31, 2026.”

COMPASS Pathways plc reported financial results for the year ended December 31, 2025.

“Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported the fourth quarter and full-year 2025 financial results and business highlights.”

COMPASS Pathways plc entered into Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC, Cantor Fitzgerald & Co., and Stifel, Nicolaus & Company, Incorporated, as representatives valued at $150.0 million (effective 2026-02-18).

“On February 18, 2026, Compass Pathways plc (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Cantor Fitzgerald & Co., and Stifel, Nicolaus & Company, Incorporated, as representatives (the “Representatives”) of the underwriters listed therein (the “Underwriters”), relating to the issuance and sale in an underwritten public offering (the “Offering”) of (i) 17,500,000 American Depositary Shares, each representing one ordinary share, nominal value £0.008 each, of the Company (the “ADSs”) at a public offering price of $8.00 per ADS, and (ii) in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs (the “Pre-Funded Warrants”) at a public offering price of $7.999 per Pre-Funded Warrant.”

COMPASS Pathways plc amended Third Amendment with Hercules Capital, Inc. valued at up to $150,000,000 (effective 2026-01-05).

“On January 5, 2026 (the “Closing Date”), COMPASS Pathways plc (the “Company”) and certain of its subsidiaries (together with the Company, the “Borrowers”) entered into the third amendment (the “Third Amendment”) to that certain loan and security agreement with Hercules Capital, Inc. (“Hercules”), dated as of June 30, 2023”

COMPASS Pathways plc incurred term loan of $150,000,000 with Hercules Capital, Inc. at the greater of (i) 9.75% or (ii) 2.75% plus the Wall Street Journal prime rate maturing January 5, 2031.

“The Amended Loan Agreement provides for five tranches of term loans in an aggregate principal amount of up to $150,000,000, consisting of (i) a term loan of $50.0 million which will be fully funded at the Closing Date (the “Tranche 1 Advance”), (ii) term loans of up to $30.0 million subject to the Borrowers achieving a clinical milestone and satisfying certain other conditions (the “Tranche 2 Advance”), (iii) term loans of up to $30.0 million subject to the Borrowers achieving a milestone relating to certain FDA approvals being granted and satisfying certain other conditions (the “Tranche 3 Advance”), (iv) term loans of up to $20.0 million subject to the Borrowers achieving a commercial milestone and satisfying certain other conditions (the “Tranche 4 Advance”), and (v) up to $20.0 million, subject to the approval of Hercules’ investment committee, as may be increased by any unborrowed amounts of the Tranche 2 Advance, the Tranche 3 Advance and the Tranche 4 Advance.”

COMPASS Pathways plc engaged PricewaterhouseCoopers LLP, United States as its auditor.

“appointed PricewaterhouseCoopers LLP, United States (“ PwC US ”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025”

PricewaterhouseCoopers LLP, United Kingdom resigned as auditor of COMPASS Pathways plc.

“accepted notice of the resignation of PricewaterhouseCoopers LLP, United Kingdom (“ PwC UK ”) as the Company’s independent registered public accounting firm and (ii) appointed PricewaterhouseCoopers LLP, United States (“ PwC US ”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025”

Gino Santini was appointed as Chairman of the Board at COMPASS Pathways plc.

“On July 30, 2024, the board of directors (the “Board”) of the Company appointed Gino Santini to join the Board and to serve as Chairman, effective September 3 , 2024, and designated him as a Class I director.”

COMPASS Pathways plc shareholders approved To waive statutory pre-emption rights on the allotment of equity securities up to an aggregate nominal amount of £820,100. at the 2024-05-09 meeting.

“Proposal 12. To waive statutory pre-emption rights on the allotment of equity securities up to an aggregate nominal amount of £820,100 . FOR AGAINST WITHHELD BROKER NON-VOTES 39,274,645 2,138,136 53,572 26,874,569 At the AGM, the Company’s shareholders approved the disapplication of pre-emption rights.”

COMPASS Pathways plc shareholders approved To authorise the directors to allot shares in the Company or grant rights to subscribe for or to convert any security into shares up to an aggregate nominal amount of £820,100. at the 2024-05-09 meeting.

“Proposal 11. To authorise the directors to allot shares in the Company or grant rights to subscribe for or to convert any security into shares up to an aggregate nominal amount of £820,100 . FOR AGAINST WITHHELD BROKER NON-VOTES 39,267,931 2,163,974 34,448 26,874,569 At the AGM, the Company’s shareholders authorized the directors to allot shares in the Company.”

COMPASS Pathways plc shareholders approved To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers for the year ended December 31, 2023. at the 2024-05-09 meeting.

“Proposal 10. To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers for the year ended December 31, 2023. FOR AGAINST WITHHELD BROKER NON-VOTES 41,098,542 101,887 265,924 26,874,569 At the AGM, the Company’s shareholders approved, on a non-binding and advisory basis, the compensation of the Company’s named executive officers for the year ended December 31, 2023.”

COMPASS Pathways plc shareholders approved To approve the Company’s U.K. directors’ remuneration policy. at the 2024-05-09 meeting.

“Proposal 9. To approve the Company’s U.K. directors’ remuneration policy. FOR AGAINST WITHHELD BROKER NON-VOTES 41,144,868 63,703 257,782 26,874,569 At the AGM, the Company’s shareholders approved the Company’s U.K. directors’ remuneration policy.”

COMPASS Pathways plc shareholders approved To receive and approve on an advisory basis the Company's U.K. statutory directors’ remuneration report for the year ended December 31, 2023. at the 2024-05-09 meeting.

“Proposal 8. To receive and approve on an advisory basis the Company's U.K. statutory directors’ remuneration report for the year ended December 31, 2023. FOR AGAINST WITHHELD BROKER NON-VOTES 41,154,238 50,843 261,272 26,874,569 At the AGM, the Company’s shareholders approved on an advisory basis, the directors’ remuneration report for the year ended December 31, 2023.”

COMPASS Pathways plc shareholders approved To receive the U.K. statutory annual accounts and report for the fiscal year ended December 31, 2023. at the 2024-05-09 meeting.

“Proposal 7. To receive the U.K. statutory annual accounts and report for the fiscal year ended December 31, 2023. FOR AGAINST WITHHELD BROKER NON-VOTES 41,405,603 42,931 17,819 26,874,569 At the AGM, the shareholders approved the receipt of the U.K. statutory annual accounts and reports for the year ended December 31, 2023.”

COMPASS Pathways plc shareholders approved To authorize the Audit and Risk Committee to determine the auditors’ remuneration for the year ending December 31, 2024. at the 2024-05-09 meeting.

“Proposal 6. To authorize the Audit and Risk Committee to determine the auditors’ remuneration for the year ending December 31, 2024. FOR AGAINST WITHHELD BROKER NON-VOTES 41,413,468 32,743 20,142 26,874,569 At the AGM, the shareholders authorized the Audit and Risk committee to determine the auditors’ remuneration for the year ending December 31, 2024.”

COMPASS Pathways plc shareholders approved Ratification of the appointment of PwC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. at the 2024-05-09 meeting.

“Proposal 5. Ratification of the appointment of PwC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. FOR AGAINST WITHHELD BROKER NON-VOTES 41,396,687 52,712 16,954 26,874,569 At the AGM, the shareholders ratified the appointment of PwC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.”

COMPASS Pathways plc shareholders approved To re-appoint PricewaterhouseCoopers LLP, an English limited liability partnership (“PwC”), as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders. at the 2024-05-09 meeting.

“Proposal 4. To re-appoint PricewaterhouseCoopers LLP, an English limited liability partnership (“PwC”), as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders. FOR AGAINST WITHHELD BROKER NON-VOTES 41,400,507 49,393 16,453 26,874,569 At the AGM, the shareholders approved the re-appointment of PwC as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders.”

COMPASS Pathways plc shareholders approved To re-elect Daphne Karydas as a Director of the Company. at the 2024-05-09 meeting.

“Proposal 3. To re-elect Daphne Karydas as a Director of the Company. FOR AGAINST WITHHELD BROKER NON-VOTES 41,406,064 36,970 23,319 26,874,569 At the AGM, Daphne Karydas was duly re-elected.”

COMPASS Pathways plc shareholders approved To re-elect Wayne J. Riley as a Director of the Company. at the 2024-05-09 meeting.

“Proposal 2. To re-elect Wayne J. Riley as a Director of the Company. FOR AGAINST WITHHELD BROKER NON-VOTES 39,378,316 2,064,175 23,862 26,874,569 At the AGM, Wayne J. Riley was duly re-elected.”

COMPASS Pathways plc shareholders approved To re-elect David Norton as a Director of the Company. at the 2024-05-09 meeting.

“Proposal 1. To re-elect David Norton as a Director of the Company. FOR AGAINST WITHHELD BROKER NON-VOTES 41,410,488 32,297 23,568 26,874,569 At the AGM, David Norton was duly re-elected.”

COMPASS Pathways plc reported three months ended March 31, 2024 results: net income $35.2 million, EPS $0.55 loss per share. Guidance initiated.

“Net loss for the three months ended March 31, 2024, was $35.2 million, or $0.55 loss per share (including non-cash share-based compensation expense of $5.1 million), compared with $24.2 million, or $0.57 loss per share, during the same period in 2023 (including non-cash-share-based compensation expense of $4.1 million).”

David Norton was appointed as Chair of the Board at COMPASS Pathways plc.

“David Norton, who currently serves as lead independent director, will assume the role of Chair of the Board.”

Ekaterina Malievskaia resigned as Director at COMPASS Pathways plc.

“On March 27, 2024, George Goldsmith and Ekaterina Malievskaia submitted their resignations from the board of directors (the " Board ") of COMPASS Pathways plc (the “ Company ”) with an effective date of March 29, 2024.”

George Goldsmith resigned as Chair of the Board at COMPASS Pathways plc.

“On March 27, 2024, George Goldsmith and Ekaterina Malievskaia submitted their resignations from the board of directors (the " Board ") of COMPASS Pathways plc (the “ Company ”) with an effective date of March 29, 2024.”

COMPASS Pathways plc reported fourth quarter and year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023, was $118.5 million, or $2.32 loss per share, EPS $2.32 loss per share.

“Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter 2023 and provided an update on recent progress across its business.”

Teri Loxam was appointed as Chief Financial Officer at COMPASS Pathways plc.

“appointed Teri Loxam as chief financial officer, principal financial officer and principal accounting officer, effective as of the later of March 1, 2024 or the filing of the Company’s annual report for the period ending December 31, 2023 (the “Effective Date”).”

COMPASS Pathways plc reported nine months ended September 30, 2023 results: net income $85.9 million, or $1.81 loss per share, EPS $1.81 loss per share.

“Net loss for the nine months ended September 30, 2023 was $85.9 million, or $1.81 loss per share (including non-cash share-based compensation expense of $13.1 million), compared with $60.6 million, or $1.43 loss per share, during the same period in 2022 (including non-cash-share-based compensation expense of $9.8 million).”

Mary-Rose Hughes was appointed as Interim Chief Financial Officer at COMPASS Pathways plc.

“Effective October 26, 2023, the Company appointed Mary-Rose Hughes as its Interim Chief Financial Officer until such time as the Company appoints a new chief financial officer.”

Michael Falvey resigned as Chief Financial Officer at COMPASS Pathways plc.

“Michael Falvey, Chief Financial Officer, principal financial officer and principal accounting officer of COMPASS Pathways plc (the “Company”), resigned from his role as chief financial officer to pursue other opportunities effective October 26, 2023.”

Daphne Karydas was appointed as Director at COMPASS Pathways plc.

“On September 13, 2023, the board of directors (the “Board”) of COMPASS Pathways plc (the “Company”), upon the recommendation of its nominating and corporate governance committee, appointed Daphne Karydas to join the Board, effective September 1 8, 2023, and designated her as a Class III director.”

COMPASS Pathways plc entered into Securities Purchase Agreement with certain institutional investors valued at approximately $125.0 million (effective 2023-08-16).

“On August 16, 2023, COMPASS Pathways plc (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue (i) 16,076,750 American Depositary Shares (“ADSs”) representing 16,076,750 ordinary shares and (ii) warrants to purchase up to 16,076,750 ADSs (representing 16,076,750 ordinary shares) (the “Warrants”), at a purchase price of approximately $7.78 per ADS and accompanying Warrant to purchase one ADS (the “Purchase Price”), in a private placement transaction (the “Private Placement”).”

COMPASS Pathways plc reported six months ended June 30, 2023 results: net income $52.5 million, or $1.19 loss per share, EPS $1.19 loss per share. Guidance reaffirmed.

“Net loss for the six months ended 30 June 2023 was $52.5 million, or $1.19 loss per share (including non-cash share-based compensation expense of $8.6 million)”

COMPASS Pathways plc reported second quarter 2023 results: net income $28.3 million, or $0.62 loss per share, EPS $0.62 loss per share. Guidance reaffirmed.

“Net loss for the three months ended 30 June 2023 was $28.3 million, or $0.62 loss per share (including non-cash share-based compensation expense of $4.6 million)”

COMPASS Pathways plc incurred term loan of $30.0 million with Hercules Capital, Inc. at greater of (i) 9.75% or (ii) 1.50% plus the Wall Street Journal prime rate maturing July 1, 2027.

“On June 30, 2023 (the “Closing Date”), COMPASS Pathways plc (the “Company”) and certain of its subsidiaries (together with the Company, the “Borrowers”) entered into a loan and security agreement (the “Loan Agreement”) with Hercules Capital, Inc. (“Hercules”), which provided for aggregate maximum borrowings of up to $50.0 million, consisting of (i) a term loan of $30.0 million, which was funded on June 30, 2023”

COMPASS Pathways plc entered into Loan and Security Agreement with Hercules Capital, Inc. valued at up to $50,000,000 (effective 2023-06-30).

“On June 30, 2023 (the “Closing Date”), COMPASS Pathways plc (the “Company”) and certain of its subsidiaries (together with the Company, the “Borrowers”) entered into a loan and security agreement (the “Loan Agreement”) with Hercules Capital, Inc. (“Hercules”), which provided for aggregate maximum borrowings of up to $50.0 million”

COMPASS Pathways plc shareholders approved To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers for the year ended December 31, 2022. at the 2023-06-02 meeting.

“Proposal 10. To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers for the year ended December 31, 2022. FOR AGAINST WITHHELD BROKER NON-VOTES 23,302,559 473,535 650,349 20,917,244 At the AGM, the Company's shareholders approved, on a non-binding and advisory basis, the compensation of the Company's named executive officers.”

COMPASS Pathways plc shareholders approved To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors' Remuneration Report for the year ended December 31, 2022. at the 2023-06-02 meeting.

“Proposal 9. To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors' Remuneration Report for the year ended December 31, 2022. FOR AGAINST WITHHELD BROKER NON-VOTES 23,616,985 415,812 393,646 20,917,244 At the AGM, the Company's shareholders approved, on a non-binding and advisory basis, the directors' remuneration report.”

COMPASS Pathways plc shareholders approved To receive the U.K. statutory annual accounts and Directors' report for the year ended December 31, 2022, and the report of the auditors thereon. at the 2023-06-02 meeting.

“Proposal 8. To receive the U.K. statutory annual accounts and Directors' report for the year ended December 31, 2022, and the report of the auditors thereon. FOR AGAINST WITHHELD BROKER NON-VOTES 24,077,293 33,791 315,359 20,917,244 At the AGM, the shareholders approved the receipt of the U.K. statutory annual account and Directors' report for the year ended December 31, 2022, and the report of the auditors thereon.”

COMPASS Pathways plc shareholders approved To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31, 2023. at the 2023-06-02 meeting.

“Proposal 7. To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31, 2023. FOR AGAINST WITHHELD BROKER NON-VOTES 24,091,310 20,993 314,140 20,917,244 At the AGM, the shareholders authorized the Audit and Risk committee to determine the auditors' remuneration for the year ending December 31, 2023.”

COMPASS Pathways plc shareholders approved Ratification of the appointment of PwC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-02 meeting.

“Proposal 6. Ratification of the appointment of PwC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. FOR AGAINST WITHHELD BROKER NON-VOTES 24,095,498 21,642 309,303 20,917,244 At the AGM, the shareholders ratified the appointment of PwC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.”

COMPASS Pathways plc shareholders approved To re-appoint PricewaterhouseCoopers LLP to serve as the Company's U.K. statutory auditor. at the 2023-06-02 meeting.

“Proposal 5. To re-appoint PricewaterhouseCoopers LLP, an English limited liability partnership ("PwC"), to serve as the Company's U.K. statutory auditor, to hold office until the conclusion of the next annual general meeting of shareholders. FOR AGAINST WITHHELD BROKER NON-VOTES 24,089,185 25,821 311,437 20,917,244 At the AGM, the shareholders approved the re-appointment of PwC as the Company's U.K. statutory auditor, to hold office until the conclusion of the next annual general meeting of shareholders.”

COMPASS Pathways plc shareholders approved To re-elect George Goldsmith as a Director of the Company. at the 2023-06-02 meeting.

“Proposal 1. To re-elect George Goldsmith as a Director of the Company. FOR AGAINST WITHHELD BROKER NON-VOTES 23,817,082 291,467 317,894 20,917,244 At the AGM, George Goldsmith was duly re-elected.”

Dr. Ekaterina Malievskaia changed role as Chief Innovation Officer at COMPASS Pathways plc.

“Dr. Malievskaia will step down from her executive role and that her employment agreement will terminate effective June 16, 2023”